GHRP-6
Growth Hormone Releasing Peptide-6
GHRP-6 was the first synthetic GHRP to be widely studied and remains one of the most characterised. As a hexapeptide ghrelin receptor agonist, it produces robust GH pulses but is distinguished by its strong appetite stimulation — a consequence of its high ghrelin receptor potency. This property makes it relevant not only for GH optimisation but as a model compound for ghrelin biology research.
Mechanism of Action
GHRP-6 activates ghrelin receptors (GHSR-1a) in both the hypothalamus and pituitary. Hypothalamic activation reduces somatostatin release (enabling larger GH pulses) and strongly activates appetite pathways — explaining the pronounced hunger effect compared to the more selective Ipamorelin.
GHRP-6 also stimulates ACTH and cortisol release at supra-threshold doses, similarly to GHRP-2. This adrenal axis co-stimulation is dose-dependent and is the main clinical limitation for long-term use compared to newer selective GHRPs.
Because GHRP-6 so closely mimics endogenous ghrelin at its target receptor, it has been extensively used in basic research to characterise ghrelin receptor biology, making it one of the most studied GHRPs despite being superseded in clinical practice by more selective compounds.
Research Evidence
GHRP-6 was one of the earliest compounds to enter GHRP clinical research, with human trials dating to the early 1990s. It has been used as a reference compound for characterising GHRP biology and ghrelin receptor pharmacology.
GHRP-6 Stimulates GH Release: Dose-Response in Healthy Adults
GHRP-6 produced robust, dose-dependent GH pulses in healthy adults with a peak at 1–3 mcg/kg IV, establishing its clinical pharmacological profile as a pituitary secretagogue.
Typical Research Protocol
Often combined with a GHRH analogue (CJC-1295 or Sermorelin). Appetite stimulation is pronounced — meal planning around dosing is important for body composition protocols where caloric control is needed. Capping at 200 mcg/injection reduces cortisol co-stimulation.
Safety Profile
Reported Side Effects
- Significant appetite increase (most common)
- Cortisol elevation (dose-dependent)
- Prolactin increase (transient)
- Water retention
- Tingling
- Headache
Contraindications
- Active malignancy
- Eating disorders (appetite amplification concern)
- Hypothyroidism
- Pregnancy
- Insulin resistance / uncontrolled diabetes
Common Research Stacks
Frequently Asked Questions
Why does GHRP-6 cause such strong hunger?
GHRP-6 potently activates ghrelin receptors (GHSR-1a), and ghrelin is the primary hunger hormone. Unlike Ipamorelin which has high GHSR selectivity for the pituitary GH-releasing pathway, GHRP-6 activates all aspects of the ghrelin receptor system — including the hypothalamic orexigenic (appetite-driving) pathways. This is intrinsic to its pharmacology and occurs even at doses that produce modest GH responses.
Is GHRP-6 more powerful than Ipamorelin?
At equivalent doses, GHRP-6 typically produces larger GH pulses than Ipamorelin, partly due to its hypothalamic somatostatin suppression effect. However, the cortisol and prolactin co-stimulation at higher GHRP-6 doses, combined with pronounced appetite stimulation, means Ipamorelin is generally preferred for sustained clean GH optimisation protocols.
Can GHRP-6 be used for muscle building?
Yes — GHRP-6 is used in body composition research. The combination of strong GH pulses (via GHSR-1a activation) with appetite stimulation (via ghrelin pathways) creates an environment favourable for muscle mass gain when combined with high protein intake and resistance training. The appetite increase, while a side effect in fat loss protocols, becomes an asset for bulk-focused research.
What is the difference between GHRP-6 and GHRP-2?
Both are hexapeptide GHRPs producing GH pulses with cortisol and prolactin co-stimulation. GHRP-6 produces stronger appetite stimulation and somewhat more pronounced cortisol elevation at equivalent doses. GHRP-2 (Pralmorelin) has more clinical data and pharmaceutical-grade manufacturing history (approved in Japan). For protocols where appetite stimulation is undesirable, GHRP-2 is slightly preferred over GHRP-6.
How should GHRP-6 be stored and reconstituted?
Lyophilised GHRP-6 should be stored at -20°C for long-term storage (up to 2 years) or 4°C for up to 6 months. Reconstitute with bacteriostatic water (BAC water) at your desired concentration. Reconstituted solution should be stored at 4°C and used within 4 weeks. Do not freeze reconstituted peptide.
Key Research References
- Bowers CY et al. (1991). On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology.
- Laferrère B et al. (1995). GHRP-6 stimulates GH secretion in humans. J Clin Endocrinol Metab.
Explore more Growth Hormone research compounds
Browse Growth Hormone →